drugset / Trial / NCT00904800

AZD0837 Extended Release (ER) Japan Study

NCT00904800

Phase 1 Completed 36 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindBasic science

Summary

This phase I study will evaluate safety and tolerability after repeated doses of AZD0837.

Timeline

Start
2009-05
Primary completion
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ATECEGATRAN METOXIL Small molecule Oral

Indications

No indication recorded.